Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: A review of studies in a relevant animal model

Comparative Medicine

Volumn 56, Issue 6, 2006, Pages 461-467

  Pollard, Morris ^a   Suckow, Mark A ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; FENRETINIDE; GENISTEIN; GLYCITEIN; ISOFLAVONE; METHYLNITROSOUREA; SOYBEAN PROTEIN; TESTOSTERONE; TESTOSTERONE PROPIONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CALORIC RESTRICTION; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DISEASE PREDISPOSITION; HORMONAL THERAPY; NONHUMAN; PRECANCER; PROSTATE CANCER; RAT; RAT STRAIN; REVIEW; SOYBEAN; TESTOSTERONE BLOOD LEVEL;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ISOFLAVONES; MALE; METHYLNITROSOUREA; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SOYBEAN PROTEINS; TESTOSTERONE;

EID: 33845666901     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Ahluwalia B, Jackson MA, Jones CW, Williams AO, Rao MS, Rajguru S. 1981. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 48:2267-2273.
2. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S-I, Itoh N, Shibuya M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine specific protein kinases. J Biol Chem 262:5592-5595.
3. Armitage P, Doll R. 1954. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 8:1-12.
4. Armstrong B, Doll R. 1975. Environmental factors and cancer incidence and mortality in different countries with special references to dietary patterns. Int J Cancer 15:617-631.
5. Axelson M, Sjovall J, Gustafson BE, Setchell KDR. 1984. Soy-a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol 102:49-56.
6. Davis J, Singh B, Bhuiyan M, Sarkan F. 1998. Genistein-induced upregulation of p21 WAF1, downregulation of cyclin B and induction of apoptosis in prostate cancer cells. Nutr Cancer 32:127-131.
7. Edwards, J, Krishna S, Witton CJ, Bartlett JMS. 2003. Gene amplifications associated with the development of hormone resistant prostate cancer. Clin Cancer Res 9:5271-5281.
8. Evans BAJ, Griffiths K, Morton MS. 1995. Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 47:295-302.
9. Fotsis T, MS Pepper, E Aktas, S Breit, S Raskau H. Adlercreutz, K Wahola, R Montesano, Schwergener L. 1997. Flavonoids, dietary-derived inhibitor of cell proliferation and in vitro angiogenesis. Cancer Res 57:2916-2921.
10. Ghanadian R, Puah KM, O'Donoghue EPM. 1979. Serum testosterone and dehydrotestosterone in cancer of the prostate. Br J Cancer 39:696-699.
11. Gottesman MH. 1993. How cancer cells evade chemotherapy. Cancer Res. 53:747-754.
12. Haas GP, Salor WA. 1997. Epidemiology of prostate cancer. CA Cancer J Clin 47:273-287.
13. Haenszel W, Kurihara M. 1968. Studies of Japanese migrants. I. Mortalilty from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43-68.
14. Harris AL. 2001. Hypoxia-a key regulatory factor in tumor growth. Nature Rev. Cancer 2:38-46.
15. Henderson BE, Feigelson HS. 2000. Hormone carcinogenesis. Carcinogenesis 21:427-433.
16. Henderson BE, Ross RK, Pike MC, Casagrande JT. 1982. Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232-3239.
17. Jemal A, Munay T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. 2005. Cancer statistics, 2005. CA Cancer J Clin 55:10-30.
18. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Fewer EJ, Thurn MJ. 2004. Cancer statistics 2004. CA Cancer J Clinic 54:8-29.
19. Joseph BJK, Vukanovic, J, Isaacs, JT. 1996. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle and breast carcinogenesis in rodents. Cancer Res 56:3404-3408.
20. Knudson AG. 1985. Hereditary cancer, oncogenes and antioncogenes. Cancer Res 45:1437-1443.
21. Knudson AG, Hethcote HW, Brown BW. 1975. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 72:5116-5120.
22. Kolonel LN. 1988. Variability in diets and its relation to risk in ethnic and migrant groups. Basic Life Sci 43:129-135.
23. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, Handa RJ. 2004. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 70:1188-1195.
24. Magee PJ, Rowland IR. 2004. Phyto-oestrogens, their mechanisms of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513-531.
25. 1. Cancer Res 53:1328-1331.
26. Maul JW. 2003. Biochemical recurrence of prostate cancer. Curr Probl Cancer 27:243-272.
27. Moolgavkar SH, Knudson SG. 1981. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 66:1037-1052.
28. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. 1987. Cancer incidence in five continents, vol v Lyon (France): International Agency for Research on Cancer. p 231-242.
29. Parkin M, Bray F, Ferlay J, Pisani P. 2002. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
30. Pollard M. 1998. Dihydrotestosterone prevents spontaneous adenocarcinomas in the prostate-seminal vesicle in aging L-W rats. Prostate 36:168-171.
31. Pollard M. 1998. Effects of linomide on advanced prostate-seminal vesicle cancers in Lobund-Wistar rats. Prostate 35:43-49.
32. Pollard, M. 2006. Personal communication.
33. Pollard M, Luckert PH. 1979. Spontaneous liver tumors in germfree Wistar rats. Lab Anim Sci 29:74-77.
34. Pollard M, Luckert PH. 1985. Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats. Prostate 6:1-5.
35. Pollard M, Luckert PH. 1986. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with n-nitroso-n-methylurea and testosterone. J Natl Cancer Inst 7:583-587.
36. Pollard M, Luckert PH. 1987. Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system. Prostate 11:219-227.
37. Pollard M, Luckert PH. 1994. Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments. Anticancer Res 14:2691-2694.
38. Pollard M, Luckert PH. 1994. The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res 14:901-904.
39. Pollard M, Luckert PH. 1997. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in LW rats. Nutr Cancer 28:41-45.
40. Pollard M, Luckert PH, Scheu J. 1995. Phenobarbital promotes the development of adenocarinomas in the accessory sex glands of MNU-inoculated L-W rats. Carcinogenesis 16:2419-2421.
41. Pollard M, Luckert PH, Snyder D. 1989. Prevention and treatment of experimental prostate cancer in Lobund-Wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration. Prostate 15:95-103.
42. Pollard M, Luckert PH, Snyder DL. 1989. Prevention of prostate cancer and liver tumors in LW rats by moderate dietary restriction. Cancer 64:686-690.
43. Pollard M, Luckert PH, Snyder DL. 1989. The promotional effect of testosterone on induction of prostatic cancer in MNU-sensitized L-W rats. Cancer Lett 45:209-212.
44. Pollard M, Luckert PH, Sporn MB. 1991. Prevention of primary prostate cancer in Lobund-Wistar rats by n-(4hydroxyphenyl) retinamide. Cancer Res 51:3610-3611.
45. Pollard M, Suckow MA. 2005. Hormone refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med 230:520-526.
46. Pollard M, Wolter W. 2000. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 45:101-105.
47. Pollard, M, Wolter W, Sun L. 2000. Prevention of induced prostate-related cancer by soy protein isolate-isoflavone-supplemented diet in Lobund-Wistar rats. In Vivo 14:389-392.
48. Pollard M, Wolter W, Sun L. 2001. Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. Cancer Lett 173:127-131.
49. Powell U, Banijec M, Saks W, Gtignon D, Wood D Jr, Novalio M. 1999. Should African American men be treated for prostate cancer at an earlier age than white men? Cancer 85:472-477.
50. Rockwell S, Yuan J, Peretz S, Glazer PM. 2001. Genomic instability in cancer. Novartis Foundation Symposium. Hoboken (NY): Wiley. p 133-151.
51. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. 1986. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76:45-48.
52. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB. 2004. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11:225-254.
53. Semenza GL, Wang WG. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietic gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454.
54. Setchell KDR, Adelcreutz H. 1988. Mammalian lignans and phytooestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In Rowland JR, editor. Role of the gut flora in toxicity and cancer. London: Academic Press. p 315-345.
55. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellini D, Wolfe BE, Nechlemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Hebubie JE. 2005. S-equol, a potent ligand for estrogen receptor B, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81:1072-1079.
56. Simoons F. 1991. Food in China: a cultural and historical inquiry. Boca Raton (FL): CRC Press. p 451
57. Snyder DL, Pollard M, Wostmann BS, Luckert PH. 1990. Life span, morphology, and pathology of diet-restricted germ-free and conventional Lobund-Wistar rats. J Gerontol Biol Sci 45:1352-1358.
58. Sporn MB. 1976. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699-2702.
59. Suetsugi M, Sun L, Karlsberg K, Ching Y-C, Chen S. 2003. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res 1:981-991.
60. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. 2001. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 93:219-225.
61. Watanabe T, Kondo K, Oishi M. 1991. Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases. Cancer Res 51:764-768.